RU2465590C1 - Method for prediction of onset of malignant growth - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: determining the immune values of saliva enables calculating a local immunity coefficient (K_mim), specifically interleukin 1, interleukin 6, tumour necrosis factor, while the local immunity coefficient is derived by formula:

wherein K_mim is the local immunity coefficient (standard units); IL1 is the saliva interleukin 1 concentration (pg/ml); IL6 is the saliva interleukin 6 concentration (pg/ml); TNG is the saliva concentration of tumour necrosis factor (pg/ml), and if the value K_mim>139.0, a high risk of developing malignant growths is stated, while the value K_mim<139.0 enables to state no risk.

EFFECT: method enables higher prediction accuracy of the onset of malignant growths with accessibility, simplicity, low power consumption and cost prices as comparison with laboratory-instrumental methods.

2 ex

Description

The invention relates to medicine, in particular to occupational medicine, and can be used to determine the adverse effects of production factors on human health, namely to assess the risk of developing cancer.

There is a method of determining the influence of the ecological situation on human health (patent 2099716, RU, class G01N 33/68), in which the level of membrane-binding catalase of peripheral blood cells is assessed in a group of workers exposed to occupational hazards or adverse environmental factors.

The disadvantage of this method is the difficulty in execution due to work with blood, requiring special treatment conditions. And also the known method determines only the collective indicator and does not allow to determine the individual health.

The well-known "Method for determining the suitability of individuals to work in conditions of chronic chemical stress of low intensity" (patent No. 2354973, RU, class G01N 33/53), taken as a prototype, which consists in determining immune parameters, which use immunoglobulins A, M, G and secretory immunoglobulin A in saliva.

The disadvantages of this method are the lack of accuracy of the method in relation to the detection of malignant neoplasms, a limited range of indications for use only for professional suitability and a restriction on the list of enterprises with a low-intensity chronic chemical load.

The objective of the claimed invention is to improve the accuracy of the method for predicting the occurrence of malignant neoplasms.

The problem is solved in that according to a method for predicting the occurrence of malignant neoplasms, including determining the salivary immune parameters and determining the local immunity coefficient (K _mim ), interleukin 1, interleukin 6, tumor necrosis factor, and the local immunity coefficient are determined by the formula :

where K _mim is the coefficient of local immunity (conventional units);

IL1 - concentration in the saliva of interleukin 1 (PG / ml);

IL6 - concentration in saliva of interleukin 6 (pg / ml);

TNF is the concentration in the saliva of tumor necrosis factor (pg / ml), and with a value of K _mim ≥139.0, a high risk of developing malignant neoplasms is judged, with a value of K _mim <139.0, no risk is judged.

Using the claimed invention allows to improve and develop prenosological diagnosis, to predict the likelihood of malignant neoplasms based on laboratory evaluation of saliva. Using this method leads to an unambiguous and definitely interpreted criterion for assessing the presence or absence of the risk of neoplasms. The method is affordable, relatively simple, low-energy and cheap in comparison with laboratory-instrumental diagnostic methods.

The claimed method is as follows. Saliva is taken for research on an empty stomach in the morning after treatment of the oral cavity with a warm, weak solution of potassium permanganate. Saliva in an amount of 2-4 ml is collected in polypropylene tubes. Secrets are processed for 3-4 hours after receipt, then frozen and stored at a temperature of -20 ° C until the moment of research. The content of interleukins and tumor necrosis factor was studied using solid-phase (heterogeneous) enzyme-linked immunosorbent assay. This method is based on the immune response of an antigen with an antibody. The advantages of the method include high sensitivity, specificity, reproducibility, uniformity and suitability for mass examinations. The results of the analysis were evaluated using a Stat Fax analyzer (USA). The reagent kits used in the work: alpha-TNF - IFA - BEST, Interleukin-6 - IFA - BEST, Interleukin-1 beta - IFA - BEST produced by Vector-Best Closed Joint-Stock Company, Novosibirsk.

Example 1

Examined A.

IL1 - 108.5 pg / ml

IL6 - 20.1 pg / ml

TNF - 23.8 pg / ml

K _mim was 50.8 srvc.

Conclusion: the value of K _mim <139.0, therefore, the development of a malignant neoplasm is unlikely in the subject. Given the effects of carcinogenic factors, it is recommended to repeat this method after 6 months.

Example 2

Surveyed B.

IL1 - 461.0 pg / ml

IL6 - 66.6 pg / ml

TNF - 58.6 pg / ml

K _mim was 195.4 srvc.

Conclusion: the value of K _mim > 139.0, therefore, the subject is highly likely to develop malignant neoplasms. An in-depth examination at a republican clinical oncology clinic is recommended. 3 weeks after the examination, V. was hospitalized in the urology department of the dispensary with a preliminary diagnosis of Cancer of the prostate gland.

Claims (1)

A method for predicting the occurrence of malignant neoplasms, including determining salivary immune parameters and determining local immunity coefficient (K _mim ), characterized in that interleukin 1, interleukin 6, tumor necrosis factor are used as immune indicators, and the local immunity coefficient is determined by the formula

where K _mim is the coefficient of local immunity (conventional units);
IL1 - concentration in the saliva of interleukin 1, (pg / ml);
IL6 - concentration in saliva of interleukin 6 (pg / ml);
TNF is the concentration in the saliva of tumor necrosis factor (pg / ml), and with a value of K _mim ≥139.0, a high risk of developing malignant neoplasms is judged, with a value of K _mim <139.0, no risk is judged.